凱萊英通過港交所聆訊
11月17日,凱萊英醫藥集團通過港交所上市聆訊,高盛與中信證券爲其聯席保薦人。凱萊英是領先的技術驅動型CDMO公司,提供貫穿藥物開發及生產全過程的綜合解決方案。
根據弗若斯特沙利文的資料,按2020年的收入計,凱萊英爲全球第五大原料藥CDMO,擁有1.5%的市場份額,且爲總部位於中國的最大型商業化階段化學藥物CDMO,擁有22.0%的市場份額。
就財務方面而言,公司於2018年,2019年,2020年及2021年上半年的收入分別爲人民幣18.23億元、24.46億元、31.37億元及17.56億元。同期,公司的毛利分別爲人民幣8.38億元、11.01億元、14.53億元及7.85億元;期內利潤分別爲4.06億元、5.52億元、7.20億元及4.29億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.